Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Accuracy of CAPRA-S Score for Predicting Long-Term Biochemical Progression After Radical Prostatectomy.

Hernández Hernández C, Kim Lee D, Sanchez Pérez M, Escobar SH.

Clin Genitourin Cancer. 2019 Jun;17(3):e645-e649. doi: 10.1016/j.clgc.2019.03.014. Epub 2019 Mar 27.

PMID:
31097389
2.

External validation of the cancer of the prostate risk assessment-s score in koreans undergoing radical prostatectomy.

Seong KT, Lim JH, Park CM, Kim HK, Park JY.

Korean J Urol. 2013 Jul;54(7):433-6. doi: 10.4111/kju.2013.54.7.433. Epub 2013 Jul 15.

3.

Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.

Beckmann K, O'Callaghan M, Vincent A, Roder D, Millar J, Evans S, McNeil J, Moretti K.

ANZ J Surg. 2018 Mar;88(3):E183-E188. doi: 10.1111/ans.13954. Epub 2017 May 4.

PMID:
28471003
4.
5.

Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.

Aktas BK, Ozden C, Bulut S, Tagci S, Erbay G, Gokkaya CS, Baykam MM, Memis A.

Asian Pac J Cancer Prev. 2015;16(6):2527-30.

6.

Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.

Punnen S, Freedland SJ, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll PR, Cooperberg MR.

Eur Urol. 2014 Jun;65(6):1171-7. doi: 10.1016/j.eururo.2013.03.058. Epub 2013 Apr 8.

7.

Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.

Murray NP, Aedo S, Reyes E, Orellana N, Fuentealba C, Jacob O.

BJU Int. 2016 Oct;118(4):556-62. doi: 10.1111/bju.13367. Epub 2015 Nov 25.

8.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
9.

Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.

May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O.

J Urol. 2007 Nov;178(5):1957-62; discussion 1962. Epub 2007 Sep 17.

PMID:
17868719
10.

Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ.

Eur Urol. 2015 Feb;67(2):326-33. doi: 10.1016/j.eururo.2014.05.039. Epub 2014 Jul 2.

11.

External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort.

Tilki D, Mandel P, Schlomm T, Chun FK, Tennstedt P, Pehrke D, Haese A, Huland H, Graefen M, Salomon G.

J Urol. 2015 Jun;193(6):1970-5. doi: 10.1016/j.juro.2014.12.020. Epub 2014 Dec 11.

PMID:
25498570
12.

Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.

Murray NP, Aedo S, Fuentealba C, Jacob O, Reyes E, Novoa C, Orellana S, Orellana N.

Urol Oncol. 2016 Oct;34(10):430.e17-25. doi: 10.1016/j.urolonc.2016.05.020. Epub 2016 Jul 2.

PMID:
27381896
13.

The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy.

Cooperberg MR, Hilton JF, Carroll PR.

Cancer. 2011 Nov 15;117(22):5039-46. doi: 10.1002/cncr.26169. Epub 2011 Jun 3.

14.

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.

Cooperberg MR, Broering JM, Carroll PR.

J Natl Cancer Inst. 2009 Jun 16;101(12):878-87. doi: 10.1093/jnci/djp122. Epub 2009 Jun 9.

15.

External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.

Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW.

Urology. 2008 Aug;72(2):396-400. doi: 10.1016/j.urology.2007.11.165. Epub 2008 Apr 18.

PMID:
18372031
16.

A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.

Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E.

Eur Urol. 2015 Apr;67(4):778-86. doi: 10.1016/j.eururo.2014.10.036. Epub 2014 Nov 12.

PMID:
25466945
17.

External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy.

Ishizaki F, Hoque MA, Nishiyama T, Kawasaki T, Kasahara T, Hara N, Takizawa I, Saito T, Kitamura Y, Akazawa K, Takahashi K.

Jpn J Clin Oncol. 2011 Nov;41(11):1259-64. doi: 10.1093/jjco/hyr136. Epub 2011 Sep 22.

PMID:
21940731
18.
19.

The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.

Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

PMID:
26749093
20.

External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series.

Loeb S, Carvalhal GF, Kan D, Desai A, Catalona WJ.

Urol Oncol. 2012 Sep;30(5):584-9. doi: 10.1016/j.urolonc.2010.06.007. Epub 2010 Sep 6.

Supplemental Content

Support Center